• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury
Conclusion and Future Aspects This review summarizes available NTF expression data, compiles existing evidence on the effects of glial NTF signaling in healthy conditions and in disease models (Figure 1), and highlights the importance of this topic for future studies. The relationship between NTFs and glia is crucial for both the developing and adult brain. While some of these factors, such as NT-3 and CNTF, have highly potent effects on gliogenesis, others like BDNF and GDNF, are important for glia-mediated synapse formation. Neurotrophic factors play significant roles during neurodegenerative disorders. In many cases, ...
Source: Frontiers in Physiology - April 25, 2019 Category: Physiology Source Type: research

Corticobasal syndrome associated with antiphospholipid syndrome without cerebral infarction
Antiphospholipid syndrome (APS) is a rare autoimmune coagulopathy with various systemic and neurologic symptoms. Ischemic stroke and TIA are common neurologic manifestations of APS, while migraine, epilepsy, chorea, and multiple sclerosis–like syndromes have also been reported.1,2 Dementia is an unusual manifestation of APS, and the presentation of APS with corticobasal syndrome (CBS) has rarely been reported.3,4 CBS is a progressive neurologic syndrome characterized by asymmetric cortical dysfunction, such as apraxia, alien limb phenomenon, or cortical sensory changes accompanied by akineto-rigid syndrome or dystoni...
Source: Neurology - February 24, 2014 Category: Neurology Authors: Lee, D.-W., Eum, S.-W., Moon, C. O., Ma, H.-I., Kim, Y. J. Tags: All Medical/Systemic disease, Corticobasal degeneration CLINICAL/SCIENTIFIC NOTES Source Type: research

Rectal administration of baclofen at the end of life
Spasticity can be a complicating symptom of a variety of neurological conditions such as multiple sclerosis, motor neuron disease, Creutzfeldt-Jakob disease, or post-stroke. Several pharmacological treatment options are available, including baclofen, tizanidine, gabapentin, botulinum toxin A and tetrahydrocannabinol/canabidiol (1, 2). However, treatment feasibility decreases as the end of life approaches, e.g. when patients are no longer able to tolerate oral medications, the onset of action would be too long, or the initiation of parenteral drug therapy (intravenous, intrathecal) is no longer indicated or appropriate.
Source: Journal of Pain and Symptom Management - August 7, 2018 Category: Palliative Care Authors: Charlotte Selge, Claudia Bausewein, Constanze Remi Source Type: research